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ABSTRACT 
CRISPR/Cas9-mediated Gene Editing in HERDA Equine 
by 
Joseph R. Hawkes, Master of Science 
Utah State University, 2019 
 
Co-Major Professors: Drs. Zhongde Wang and Dirk Vanderwall 
Department: Animal, Dairy, and Veterinary Sciences 
 
To date, no research group has published gene editing in Equine. Heritable Equine 
Regional Dermal Asthenia (HERDA) is an autosomal recessive genetic skin disease 
found mainly in elite American Quarter Horse breeding lines. HERDA is caused by a 
single nucleotide mutation (c.115 G>A) in exon 1 of the peptidyl-prolyl Isomerase B 
(PPIB) gene. HERDA-affected horses are not suitable for performing and are oftentimes 
euthanized. Any prospect of “breeding out” HERDA from American Quarter Horses is 
unlikely, given the wide spread HERDA-causing mutation among elite American Quarter 
Horses. 
Since no effective treatment exists for HERDA, it representing an opportunity to 
use gene editing to correct this genetic disease. In this thesis project, CRISPR/Cas9 and 
adenine base editor 7.10-max (ABEmax) were employed to edit the HERDA-causing 
mutation in equine fibroblasts. I designed a single guide RNA (sgRNA) to direct 
CRISPR/Cas9 to induce double strand breaks (DSBs) 15 nucleotides (nt) downstream of 
the mutation which achieved very efficient insertions or deletions (indels) (~90%). 
Assisted by a small 100nt. reverse compliment single-stranded donor oligonucleotide as 
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template, CRISPR/Cas9 edited the HERDA-causing mutation in equine fibroblasts with 
~10% efficiency. Four single-cell derived colonies, out of 41, were established from 
transfected cells and genetically characterized, and showed both monoallelic and biallelic 
gene editing frequencies of 7.3% and 2.4% respectively. The colonies were 
cryopreserved for future animal cloning experiments to produce HERDA-free animals. 
Performance evaluation of the cloned animals may also to answer the question on 
whether the HERDA mutation is linked to the extraordinary flexibility of joints and super 
performance of elite horses. 
Lengthening the highly efficient sgRNA that was used with CRISPR/Cas9 by 2 
nucleotides broadened the base editing window, giving ABEmax access to the HERDA-
causing mutation at protospacer position 19. Horse fibroblasts were transfected with 
ABEmax, where single-cell colony selection and sequencing revealed seamless A to G 
conversion in 3 out of 20 single-cell colonies. Another 40% of isolated colonies may 
have been edited but carry an unspecific PCR band. Further investigation is needed to 
determine these genetic alterations. 
(74 pages) 
 
 
v 
 
PUBLIC ABSTRACT 
 
CRISPR/Cas9-mediated Gene Editing in HERDA Equine 
Joseph R. Hawkes 
 
 HERDA (Heritable Equine Regional Dermal Asthenia) is a genetic skin disease 
mainly found in Quarter Horses, but also in Appaloosa and American Paint breeds. 
HERDA is similar to Ehlers-Danlos syndrome in humans, with symptoms including 
stretchy skin, hyperflexible joints, and, unique to HERDA equine, spontaneous skin 
sloughing. Horses affected by HERDA are not suitable for performing and are oftentimes 
euthanized. Some carriers for the HERDA-mutation are very competitive in the American 
Quarter Horse industry, especially in cutting events where it is believed, yet unproven, to 
give them an advantage with increased flexibility. It is also possible that the genomic 
locus (or loci) that links to the competitive performance traits is located close to the 
HERDA-causing mutation, which could lead to the co-segregation of this performance 
trait with the HERDA-causing mutation.  
 Direct-line breeding strategies in the last 30 years have increased the number of 
HERDA-affected equine causing this disease to increase in frequency among the Quarter 
Horse breed. Since no treatment exists for HERDA, owners often heavily invest in 
HERDA horses before the symptoms arise at around two years of age. These horses are 
often euthanized to alleviate pain and stress on the horse and to mitigate the costly 
upkeep by the owner.  
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 HERDA-affected horses carry a homozygous single nucleotide mutation (c.115 
G>A) in exon 1 of peptidyl-prolyl Isomerase B (PPIB). Gene editing approaches would 
be preferable for correcting this genetic disease, since it can precisely correct the 
mutation without altering any other genetic traits in the elite horse breeds that have been 
heavily selected for. By employing the CRISPR/Cas9 system, we have sought to correct 
the HERDA-causing mutation in the PPIB gene. The CRISPR/Cas9 system is comprised 
of a bacterial endonuclease protein called Cas9 and a guide RNA sequence to direct Cas9 
to target the genome in a sequence-specific manner by introducing DNA double-strand 
breaks (DSBs). The introduction of DNA DSBs promotes the activation and recruitment 
of homologous recombination (HR)-mediated DNA repair machineries to repair the 
broken DNA; if oligonucleotides with the desired DNA sequence are co-delivered with 
the CRISPR/Cas9 system into cells, the HR-mediated DNA repair mechanism can 
replace the targeted sequence in the genome with the oligonucleotide’s sequence, 
therefore, achieving gene correction or editing. We designed sgRNAs to target genomic 
sequences in close vicinity of the HERDA-causing mutation and a single-stranded DNA 
oligonucleotide containing the normal (wild type) PPIB genotype. Co-delivery of the 
CRISPR/Cas9/sgRNA complex with the donor oligonucleotide has successfully led to the 
production of gene edited cells. We established single-cell derived colonies from the 
edited cells and achieved 7.3% monoallelic and 2.4% biallelic editing frequencies. The 
gene edited fibroblasts were cryopreserved as an initial step for future HERDA-free 
equine cloning projects to develop the first gene edited horses.  
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We also investigated novel approaches to correct the HERDA-causing mutation 
by means of Adenine Base Editors (ABEs). Optimized for mammalian expression, 
ABEmax is composed of the Cas9 nickase fused to TadA, a tRNA adenosine deaminase 
lab-evolved to catalyze A to G base conversions in DNA. Seamless base editing was 
achieved in 15% of single-cell derived colonies, correcting the HERDA-causing 
mutation, while unusual genotypes were detected in 40% of isolated colonies.  
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 CHAPTER I 
INTRODUCTION 
 
Hereditary Equine Regional Dermal Asthenia (HERDA) is an autosomal 
recessive disease of American Quarter horses, with the highest prevalence in reining and 
cutting horses (A. Rashmir-Raven, 2013). HERDA is caused by a single-nucleotide 
missense mutation (c.115G>A) in exon 1 of the peptidyl-prolyl Isomerase B (PPIB) gene 
which codes for cyclophilin B (CypB) protein (Tryon, White, & Bannasch, 2007). The 
HERDA-causing mutation alters CypB’s interaction with other collagen-folding 
enzymes, delaying collagen folding, decreasing collagen tensile strength, and propagating 
disorganized fiber packing (Bowser et al., 2014; Brounts, Rashmir-Raven, & Black, 
2001; Grady, Elder, Ryan, Swiderski, & Rashmir-Raven, 2009; Ishikawa et al., 2012). 
Symptoms include fragile skin, prone to ulcerative lesions, spontaneous skin sloughing, 
hypermobility, subdermal hematomas, and decreased cornea thickness (Badial et al., 
2015; A. M. Rashmir-Raven & Spier, 2015). 
In Rashmir-Raven’s study (2013), HERDA-affected equines reportedly begin 
showing pathological lesions by age two, when the horse is saddled to begin riding, while 
some do not develop the disease until 4-5 years old, or occasionally, never develop 
typical skin lesions, though hyperelastic (i.e., “stretchy) skin is present. She found that 
occasionally, mildly affected horses are sound enough to compete, while some, aided by 
great care, have lived into their late 20’s. Due to increased DNA testing availability and 
HERDA awareness, most horses with HERDA are humanely euthanized by age 3, but 
Rashmir-Raven notes that often, HERDA is diagnosed after considerable financial and 
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emotional investments have been made. She also reports that the number of horses 
affected by HERDA is increasing due to the common practice of line breeding carrier 
horses, to the point that today, HERDA is one of the most commonly reported inherited 
diseases in the equine industry. HERDA-affected Quarter Horses, Appaloosas, and 
American Paints are found throughout the world, reported in at least the United States, 
Canada, Mexico, Brazil, England, France and the Netherlands (Badial et al., 2015; 
Rendle, Durham, & Smith, 2010; Tryon et al., 2009; White & Bourdeau, 2011). Truly, 
HERDA is a world-wide issue without a cure. 
Gene-editing technology provides an opportunity to correct the HERDA-causing 
mutation, as a solution for alleviating animal suffering without euthanasia and 
propagating these elite genetic carrier lines without HERDA. Gene editing of 
performance horses, either heterozygous or homozygous for the HERDA-causing 
mutation, could offer horse breeders more flexibility in selecting mating pairs as edited 
clones would be restored to wild-type, free of the mutation.  
Originally derived from microbial adaptive immunity, clustered regularly 
interspaced short palindromic repeats (CRISPR) has been harnessed to mediate 
targeted and efficient modification of virtually any location within the eukaryotic 
genome by a short RNA guide (Cong et al., 2013a). In complex with the guide RNA, 
CRISPR-associated endonuclease Cas9 can base pair with the sequence of interest, 
thereafter inducing double-strand breaks (DSBs) (Jinek et al., 2012). This DNA 
cleavage may result in insertions or deletions (indels) which disrupt the gene in an 
uncontrollable manner, or through the Homology Directed Repair Pathway, available 
with a sister chromatid or provided DNA template which edits the gene (Hsu, Lander, 
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& Zhang, 2014).  Precise short gene editing (< 50bp) may be achieved by providing the 
cells with a short single-stranded oligodeoxynucleotide (ssODN), designed to have 
~50-80bp homology arms of varying symmetry around the DSB and sense in relation 
to the PAM-containing strand (Paquet et al., 2016; Richardson, Ray, DeWitt, Curie, & 
Corn, 2016; Wang et al., 2016). For large insertions/deletions (>100bp), plasmid donors 
are commonly used with 800bp homology arms. Co-delivered with CRISPR/Cas9, the 
donor ssODN or plasmid instructs the cell repair machinery which mutations to 
integrate or retract from the cellular DNA (Yang et al., 2013).  
In order to increase editing efficiency and reduce indels, base editor technology 
was developed by David Liu’s group at the Broad Institute of MIT and Harvard (Gaudelli 
et al., 2017). They describe the Adenine Base Editor (ABE) as a Cas9 nickase fused to 
Escherichia coli TadA, a tRNA adenosine deaminase, which acts on DNA instead of its 
usual RNA substrate. In the process of A to G conversion, they describe an intermediate 
called inosine, which is converted to guanosine along with the complimentary thymine-
base converted to cytosine, after either DNA replication or repair. In order to target a 
specific adenine base for editing, ABE uses an NGG protospacer adjacent motif (PAM) 
and 20nt guide RNA to edit adenine bases within an editing window of positions 13-17 
upstream of the PAM sequence. 
ABE7.10 was the first ABE version developed by Gaudelli (2017) which 
catalyzed an A (adenine) to G (guanine) conversion in ~50% of human cells with very 
low INDEL rates (typically ≤0.1%). Although much more efficient than Cas9 nuclease 
and ssODN editing, Koblan (2018), from the same group, reported that ABE7.10 editing 
bottlenecks in the process of plasmid expression, which reduces base editing efficiency. 
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His group optimized ABE7.10 by modification of nuclear localization signals and codon 
usage, and ancestral reconstruction of the deaminase component. The resulting ABEmax 
editor corrects mutations with ~5 to 7-fold greater efficiency than ABE7.10 and generates 
indels rarely (≤1.6%) although elevated from the virtually undetectable indel levels of 
ABE7.10. 
Another base editing tool was developed by Feng Zhang’s group at the Broad 
Institute of MIT and Harvard to convert A to I (inosine) in RNA instead of DNA 
(Abudayyeh et al., 2017; Cox et al., 2017). They fused Cas13b RNA nuclease to ADAR, 
a human deaminase that catalyzes A to I conversion in RNA, naming it REPAIR (RNA 
Editing for Programmable A to I Replacement). They reported that REPAIR can be used 
to selectively edit adenosine to inosine in RNA when used in conjunction with a guide 
RNA where inosine is read as guanosine by translational machinery. Additionally, 
REPAIR does not require PAMs or operate within a base editing window, but rather 
requires modification and delivery of a 50bp guide RNA, where a base flip (C) at the 
target A directs base conversion optimally at protospacer position 37 (Matthews et al., 
2016). Zhang’s group (2017), developed several versions of REAPIR where a mutation in 
the ADAR deaminase domain confers increased specificity, and Cas13b is truncated for 
adeno-associated virus (AAV) expression. With these modifications, Cas13b has 
powerful potential as a gene therapy tool. 
This thesis project is the first to implement CRISPR/Cas9 to correct the 
HERDA-causing mutation in equine fibroblasts, in anticipation of cloning the first 
gene-edited horses by using the gene-edited fibroblasts as nuclear donors. In parallel, 
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research was also carried out to establish DNA and RNA editing techniques in equine 
for developing therapeutics for affected horses.  
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REVIEW OF LITERATURE 
 
Hereditary Equine Regional Dermal Asthenia 
Hereditary equine regional dermal asthenia (HERDA) is an autosomal recessive 
skin disorder that affects primarily American Quarter Horses (A. Rashmir-Raven, 2013). 
In a clinical study by Borges and associates (2005) in Brazil, they noted that HERDA is 
also known as hyperelastois cutis, as it belongs to a group of inherited congenital 
connective tissue dysplasias. They reported clinical sign of the disease from three horses 
with HERDA, where they found that tender bilateral lesions of their trunk and lumbar 
regions cause the horse pain upon handling. They also demonstrated that these sensitive 
regions contain hyperelastic skin due to thinner and smaller collagen fibrils which are 
loosely organized. In White’s study (2014), it was reported that horses begin showing 
additional HERDA disease signs such as skin lesions, seromas, and hematomas by one 
and a half years of age, after saddling which commonly causes lesions along the dorsal 
aspect in HERDA-affected equine. Rashmir-Raven (2013) also found that HERDA-
affected horses have an increased range of motion in their joints and greater ligament 
elasticity than other horses.  
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Figure 1. Clinical signs of HERDA in Affected Equine. A) Spontaneous skin 
sloughing in a 2‐year‐old Quarter Horse filly (Hrd/Hrd), typical of a horse severely 
affected with HERDA. B) Disfiguring scars on a 6‐year‐old Quarter Horse stallion with 
HERDA (Hrd/Hrd) C) An example of ‘doughy’ skin on a 3‐year‐old Quarter Horse 
gelding with HERDA (Hrd/Hrd). This horse was gelded at approximately 18 months of 
age without ill effects. D) An example of loose, hyperextensible skin on a 3‐year‐old 
Quarter Horse gelding with HERDA (Hrd/Hrd). This horse was also gelded at 
approximately 18 months of age without ill effects. (Rashmir-Raven and Spier, 2015).  
 
Rashmir-Raven and Spier (2015) later demonstrated that HERDA-affected horses 
exhibit loose, stretchy, hyperextensible skin that is easily pulled away from the body 
(Figure 1D). They reported that affected areas of the abnormal skin may range from a 
small area of 2-3 cm in diameter to 80% of the horse’s body; some skin becomes so 
fragile that it sloughs off, leaving disfiguring scars, common among HERDA equine 
(Figure 1B). Also, they noted that oddly, some horses do not develop lesions until 4yrs 
old or later while other horses appear to never develop lesions, although they exhibit 
A B 
C D 
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hyperextensible skin and signs of discomfort when saddled. Their research indicates that 
males appear to be most severely affected.  Although HERDA-affected equine show poor 
recovery from some wounds, successful healing may occur after routine or traumatic 
repair surgeries (Castori et al., 2012). 
Rashmir-Raven (2013) reports that other skin conditions may mimic HERDA 
phenotype, especially Alopecia (horse baldness), often worrying the horse owners 
whether their horses are affected by HERDA. She and Brown (2015) list other skin 
conditions sometimes confused with HERDA, which include “Rain Rot” (bacterial skin 
infection), mud fever, sweet itch, hives, sunburn, warts, ringworm, mange, or lice. 
 
  
Figure 2.  Joint Hypermobility in HERDA-affected (Hrd/Hrd) Equine. A yearling 
American Paint Colt undergoing two types of leg stretches, revealing an abnormal range 
of motion (Rashmir-Raven, 2013). 
 
Histopathological Signs and Identification 
In separate clinical studies, groups led by Badial (2015), Bowser (2014), 
Brinkman (2017), (Gardner, Arnoczky, & Lavagnino, 2011) and Grady (2009) reported 
that HERDA-affected equine may show signs of the disease not only in skin and joints 
but also the cornea, great vessels, tendinoligamentous structures, and heart valves. They 
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also noted that these horses have higher amounts of total soluble collagen than unaffected 
horses, osteoarthritic lesions, increased joint inflammation, greater incidence of corneal 
opacities, decreased corneal thickness, abnormal collagen fibril arrangement, and weaker 
(lower tensile strength) tendinoligamentous tissues and great vessels.  
 
 
Figure 3. Dermal Lesions Observable in HERDA-affected Equine.  A) Hematoma on 
the withers of an affected horse, caused by blood and serum accumulation in the upper-
deep dermis. B) Dorsal skin ulcerations complicated by UV radiation and saddle riding 
(Tyron et al., 2007).  
 
A group led by Brounts (2001) analyzed tissues from HERDA-affected equine, 
and found that thinning and fragmentation of the skin may result in separated skin layers 
where the space between layers fills with fluid, forming large blisters (bulla) and 
hematomas (Figure 3A). In some areas, the upper half of the skin is completely separated 
from the lower half of the deep dermis by a cleft-like space, known as zonal dermal 
separations (Figure 4C).  Also present in the deep dermis are interstitial 
microhemorrhages and increased vascularity (Brounts et al., 2001).  
 
 
 
A B 
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Figure 4. HERDA Collagen Fiber Organization. Dermal skin biopsy from a 1yr. old 
filly affected with HERDA, fixed on a slide an imaged by electron microscopy (TEM; 
x54,000). A) Variations in collagen fiber diameter, a trait unique to HERDA, B) collagen 
fibers packed in a loose and unorganized fashion, C) cross-section revealing the 
separation of the superficial and deep dermis (Brounts et al., 2001). 
 
 
Potential Environmental Influences on HERDA Equine 
  The reason for variation in affected horses’ clinical signs is partially unknown, 
while potential environmental influences my play a role in severity of the disease. UV 
light appears to increase severity of HERDA, by the disease’s manifestation on the dorsal 
midline where UV light hits more directly and heat is also more intense (Rashmir-Raven, 
2013). UV light exposure disrupts the dermal extracellular matrix by activating matrix 
metalloproteinases (MMPs) including collagenases (Rittié & Fisher, 2002). Due to 
delayed collagen folding and loosely packed/disorganized collagen fibers, the MMPs 
may degrade collagen more rapidly than in humans (A. M. Rashmir-Raven & Spier, 
2015). Rashmir-Raven (2013) reports that horses with dermal lesions often show signs of 
A B 
C 
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recovery after being moved indoors for 2-4 weeks. She also notes that colder weather, 
UV light protective sheets, and northern climates also decrease the effects of HERDA (A. 
Rashmir-Raven, 2013). 
Palliative Treatments 
No effective treatment for HERDA exists (White, 2014). Rashmir-Raven and 
Spier (2015) suggest that palliative therapy, which focuses on preventing or relieving 
symptoms, for HERDA-affected equine, includes administering phenylbutazone and 
chondroprotective nutraceuticals. They mention that some horse owners strongly 
recommend supplementing HERDA horses with lysine, but its benefits are not medically 
confirmed. Rashmir-Raven (2013) suggests that supplementing horses with dietary 
copper and vitamin C may help manage HERDA, but concludes that minimizing trauma, 
careful wound management, and restriction from heat and sunlight are some of the best 
ways to care for HERDA-affected equine. 
HERDA Mutation Origin 
Hedgepeth (1990) explains that the Quarter Horse breed originated from crosses 
between English and Spanish horses as early as 1611 that were originally bred for their 
use in short quarter-mile races in colonial America. These horses were later interbred 
with the Mustang, where he adds that during the American Westward migration, these 
“Quarter Horses”, as they became known, were invaluable for their versatility, strength, 
and agility, as they were employed in ranches and cattle management.   
Although HERDA was first reported in young Quarter horses in 1978, this 
mutation has been traced back to a Quarter Horse foundation sire, Poco Bueno who was 
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foaled in 1944 (A. Rashmir-Raven, 2013; Tilstra & Byers, 2002). Rashmir-Raven (2013) 
recounts that Poco Bueno was immensely popular, gentle, smart, and easy-to-handle. She 
and the American Quarter Horse Association (AQHA) (2010) report that he remained an 
influential sire during the 1940s, ‘50s and ‘60s—siring 405 registered foals, 50% of 
which were carriers for HERDA. The AQHA (2010) also records that 36 of his offspring 
were AQHA champions, 3 of which, as confirmed carriers, were inducted into the 
National Cutting Horse Association Hall of Fame, and later, in 1990, Poco Bueno was 
inducted posthumously. 
A group led by Tryon (2007) concluded that robust breeding of HERDA carrier 
stallions has caused inbreeding loops, where many affected horses’ pedigrees trace back 
to the popular sires bred in the late 1990s, resulting in higher incidence HERDA-affected 
equine. Out of 5000 horses’ DNAs tested, 55 were found homozygous for the HERDA-
causing mutation (Hrd/Hrd), whose lineages trace back to Poco Bueno. In a separate 
evaluation of 75 HERDA-affected horses, 100% exhibited consanguinity to Poco Bueno 
within seven generations (Rashmir-Raven et al., 2013). Today, carrier frequency of the 
HERDA-causing mutation is estimated at 3.5% in the overall American Quarter Horse 
population but estimated at 28.3% in elite cutting horses (Tryon et al., 2009). HERDA is 
now reported as one of the most common diseases in the equine industry, reported in 
Quarter Horses, Appaloosas, and American Paint Horses. In a study of Brazilian Quarter 
Horses, Borges’s group (2005) estimated HERDA allele and carrier frequencies at 2.9% 
and 5.8%, respectively (Badial et al., 2015; Rendle et al., 2010; Tryon et al., 2009; White 
& Bourdeau, 2011). HERDA is a world-wide issue without a cure that many horse 
owners encounter. 
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Genetically Testing Equine for HERDA  
 In order to prevent the spread of HERDA, the AQHA (2018) requires breeders to 
complete the DNA (parentage) and panel tests on stallions and report which mares were 
bred. They offer a five-panel genetic test which covers HERDA, glycogen branching 
enzyme deficiency, hyperkalemic periodic paralysis, malignant hyperthermia, and 
polysaccharide storage myopathy. Breeders may order a kit online through the AHQA 
website and mail in a DNA sample of about 50 tail hairs for genotyping, where samples 
are processed by the University of California-Davis for HERDA. Current panel tests cost 
$100 for AQHA members or $155 for nonmembers, and results may be obtained in about 
two weeks. Some universities offer HERDA genotyping services, diagnosing through 
Restriction Fragment Length Polymorphism (RFLP) analysis (University of California-
Davis) where the difference in homologous DNA sequences can be detected by the 
presence of differing PCR fragments after restriction enzyme digest (Figure 5A), or 
sanger sequencing (Figure 5B) (Texas A&M University) (Heather & Chain, 2016) NCBI, 
2017). 
Although several groups refer to horse zygosity for the HERDA-causing mutation 
differently, this thesis project refers to the three genotypes as wild type (WT/WT); 
carriers (WT/Hrd), which are heterozygous for the HERDA-causing mutation, and 
(Hrd/Hrd) which are homozygous for the HERDA-causing mutation. 
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Figure 5. Genotyping Horses for the HERDA-causing mutation. A) Restriction 
Fragment Length Polymorphism (RFLP) analysis where DNA fragments are sorted by 
length in gel electrophoresis and B) Sanger Sequencing to identify the HERDA-causing 
mutation in equine. The horses Coralee, Eunice, and Eileen are wild type (WT/WT); Nike 
and Solo carry the mutation (WT/Hrd) and Max is homozygous for the mutation 
(Hrd/Hrd). The HERDA mutation is circled in red, the mutant glycine to arginine change 
(p.39G>R) is boxed in yellow. The blue arrow indicates the double peak for HERDA 
carriers. 
 
Molecular Basis for HERDA 
The HERDA-causing mutation, located on equine chromosome 1 (ECA1), was 
identified by Tryon’s group (2007), with fine-structure single nucleotide polymorphisms 
(SNPs) mapping. They compared the HERDA PPIB gene sequence to other species such 
as human, chimpanzee, dog, cow, mouse, and Quarter Horses (Figure 6). They identified 
the correlation between the HERDA-causing mutation (c.115G>A) and HERDA-affected 
individuals in results from assaying samples of 64 HERDA-affected horses with a control 
group of 1079 horses. Additionally, extracellular cyclophilins, such as cyclophilin B 
(cypB) of the PPIB gene, have been reported to be associated with procollagen 
processing and inflammatory response  (Arora et al., 2005; Bachinger, Morris, & Davis, 
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1993; Smith, Ferreira, Hebert, Norris, & Sauk, 1995; Steinmann, Bruckner, & Superti-
Furga, 1991). 
 
Figure 6. HERDA PPIB Protein Alignment. Equine PPIB shares 97% identity with 
canine PPIB, while it is 88% identical with the six-mammalian species in this figure. 
*HERDA-causing mutation (c. 115G>A), results in a glycine to arginine change (p. 
39G>R) in the putative N-terminal domain of the cyclophilin B protein, otherwise 
conserved in all other sequenced vertebrates. (Tryon et al., 2007). 
 
CypB has been shown to play a major role in the biosynthesis of procollagens, as 
it interacts with the many collagen-modifying enzymes, such as P3H1-CRTAP-CypB 
complex, calnexin, calreticulin, calmegin, HSP47, and protein-disulfide isomerase 
(Chang, Barnes, Cabral, Bodurtha, & Marini, 2009; Ishikawa, Vranka, Wirz, Nagata, & 
Bächinger, 2008; Kozlov, Määttänen, Thomas, & Gehring, 2010; Smith et al., 1995; J. 
Zhang & Herscovitz, 2003). CypB participates in proline residue 3-hydroxylation, and 
after triple helix formation, CypB and other cyclophilins catalyze the rate-limiting step of 
peptide bond cis-trans isomerization (Bächinger, 1987; Bachinger et al., 1993; Steinmann 
et al., 1991). Procollagen then folds with the assistance of special chaperones including 
HSP47 and FKBP65 as likely candidates (Ishikawa et al., 2012, 2008; Makareeva & 
Leikin, 2007). Ishikawa’s group (2012) discovered that the HERDA-causing mut-CypB 
protein has a disordered side chain where Arg-6 predominantly occupies the position of 
normal lys-5 (Figure 7), displacing the main chain and preventing normal interaction with 
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the P-domain of procollagen modifying enzymes and chaperones. They suggest that 
mutCypB’s interactions with collagen-folding chaperones results in delayed collagen 
folding in this rate-limiting step, affecting its secretion into the extracellular matrix, 
which was confirmed when they detected decreased hydroxylysine residues in collagen 
fibrils from HERDA-affected equine. 
 
 
Figure 7. HERDA PPIB (CypB) Crystal Structure. Three superimposed crystal 
structures of horse WT CypB (green), horse HERDA mut-CypB (red), and human WT 
CypB (white) in a duplex with the proline-rich P-domain of calmegin (yellow). Note the 
displacement of Lys-5 (green arrow) and occupation of normal Lys-5 position by Arg-6 
(shown as sticks; indicated by orange arrow) in HERDA CypB, leading to significant 
displacement of the main chain and preventing normal interaction with calmegin’s P-
domain. Although only calmegin P-domain is shown here in complex with CypB, the P-
domains of several procollagen modifying enzymes and chaperones interact with CypB, 
such as calreticulin, lysyl hydroxylase 1 the P3H1-CRTAP-CypB complex, and others 
(Ishikawa et al., 2012) 
 
Ehlers-Danlos Syndrome 
HERDA is clinically similar to Ehlers-Danlos syndrome type VIA (EDSVI) in 
humans, which is categorized within a larger group of connective tissue fragility 
syndromes (A. Rashmir-Raven, 2013). Ehlers-Danlos Syndrome (EDS) is caused by 
mutations in genes encoding various collagen types, collagen-modifying enzymes, and 
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other critical components of the dermal extracellular matrix (Mao & Bristow, 2001a; 
Myllyharju & Kivirikko, 2004a; Seidler et al., 2006). EDSVI is caused by a deficiency of 
lysyl hydroxylase 1 due to PLOD1 gene mutations and is inherited autosomal recessively 
(Hautala, Heikkinen, Kivirikko, & Myllyla, 1993; Wilcox, 2003). EDSVI is characterized 
by hypotonia (muscle weakness) at birth; progressive kyphoscoliosis (abnormal posterior 
and sideways curvature of the spine); skin hyperelasticity and fragility; joint 
hypermobility and subluxations; microcornea; rupture of arteries and the eye globe; 
and/or osteopenia (bone weakness) (Beighton, De Paepe, Steinmann, Tsipouras, & 
Wenstrup, 1998). Occurrence of EDSVI in humans is estimated at 1:100,000 (Yeowell & 
Steinmann, 2014). Classical EDS of hypermobile and classical forms are most common, 
affecting between 1 in 5,000 to 20,000; other forms of EDS are rare, often linked to 
affected families (Tilstra & Byers, 2002).  
 
 
Figure 8. Phenotypic Similarities between HERDA and Ehlers-Danlos Syndrome. A) 
Hyperextensible skin in a human patient affected by Ehlers-Danlos syndrome (Malfait, 
Wenstrup, & De Paepe, 2010) and B) hyperelastic skin characteristics in HERDA-
affected equine (White, 2014). 
 
 
Mutations affecting enzymes involved in post-translational modification of 
collagens have been associated with autosomal recessive forms of EDS in humans and 
B A 
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with similar recessive syndromes in animals (Colige et al., 2002; Mao & Bristow, 2001b; 
Myllyharju & Kivirikko, 2004b). The most common mutations for Ehlers Danlos affected 
humans occur in collagen genes, with 75% occurring in Col5A1 gene, while null 
mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta 
(Marini, Cabral, & Barnes, 2010; Ritelli et al., 2013; Symoens et al., 2012). 
 Two novel mutations in the PPIB gene were recently reported by Jiang’s group 
(2017) in a rare pedigree from a Chinese cohort with autosomal recessive osteogenesis 
imperfecta type IX. With next-generation sequencing (NGS), they sequenced the parents’ 
whole exomes, revealing that the father carried a PPIB (c.25A>G) mutation in exon 1 and 
the mother carried a PPIB (c.509G>A) mutation in exon 4. These human cases of EDS 
hypermobility type (HEDS) represent the most similarity to the HERDA-causing 
mutation (c.115G>A) in location and type, where gene editing the HERDA-causing 
mutation in equine could potentially serve as a model for curing EDS in humans. 
EDS has been observed in Quarter Horses, not affected by HERDA. In one study 
by Steelman’s group (2014), a 7-year-old black Quarter Horse gelding, in good body 
condition, had a 12-month history of skin lesions and scarring but did not exhibit joint 
hypermobility or ocular abnormalities normally associated with the HERDA, nor did it 
have any relation to HERDA-affected horses. The group performed a necropsy, which 
revealed fibrous lesions of the withers and tenting lesions on dorsal skin (Figure 9). 
Additionally, they found that collagen fibers were slightly fragmented and tissue layers 
were separated throughout the skin. Although they did not discover a genetic mutation as 
a cause for this case report, the group hypothesized that a novel and likely spontaneous 
mutation in the many collagen synthesizing, propeptide cleaving, or folding associated 
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proteins is responsible for the observed Ehlers-Danlos symptoms, and suggests that 
horses with similar clinical signs without the PPIB mutation should be classified as 
having EDS. 
 
 
 
 
 
 
Figure 9. Non-HERDA Clinical Signs of Ehlers-Danlos in Equine. Gross lesions 
revealed by autopsy of a 7-year-old gelding with Ehlers Danlos syndrome, which tested 
negative for HERDA. A) Skin tenting resulting from lesions. B) Dermal separation 
characteristic of HERDA but observed in this equine with Ehlers Danlos (Steelman et al., 
2014). 
 
 
CRISPR/Cas9 
 Since HERDA is caused by the single-nucleotide mutation (c.115G>A) in exon 1 
of PPIB gene, several gene editing tools may be employed to genetically reverse it 
(Paquet et al., 2016; Tryon et al., 2007). Type II CRISPR (clustered regularly interspaced 
short palindromic repeats)/Cas9 (CRISPR associated protein 9) is derived from the 
adaptive prokaryotic immune system and targets genomic DNA sites, guided by short 
single-stranded guide RNA (sgRNA). After Cas9 binds to target loci, it nicks both strands 
of DNA, generating double strand brakes (DSBs) which generally result in indels but 
with a donor oligonucleotide template present, can stimulate cellular repair machinery to 
incorporate desired edits to genomic DNA (Cong et al., 2013a). CRISPR/Cas9 has 
improved the efficiency of genetic engineering which replaces previous gene editing 
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tools like designer zinc fingers (ZFs), transcription activator-like effectors (TALENs) 
which required homodimer formation (McCarty, Kleiger, Eisenberg, & Smale, 2003). 
 
Figure 10. Targeting Genomic DNA with CRISPR/Cas9. Schematic representation of 
CRISPR/Cas9 targeting genetic loci and inducing DSBs. After complexing with the guide 
RNA, Cas9 is directed to a gene of interest, cuts both DNA strands, and triggers DSB 
repair, which may result in indels or HDR which may introduce desired edits if an 
oligonucleotide donor is present (Ding, Li, Chen, & Xie, 2016). 
 
CRISPR loci in the bacterial genome are composed of DNA repeat sequences (21-
48bp) that are flanked with spacers (27-72bp), as observed in Thermophilus bacterial 
response to phage infection during milk fermentation (Labrie, Samson, & Moineau, 
2010). Many phage-resistant bacteria carry CRISPR-Cas systems with multiple repeat-
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spacers identical to the infectious phage genomic sequences; for example, 
Methanococcus jannaschii contains up to 20 CRISPR loci in its genome, and CRISPR 
loci can be transferred horizontally via conjugation (Deveau, Garneau, & Moineau, 
2010). Defense against phages occurs in two phases: adaptation and interference (Agari 
et al., 2010; Horvath & Barrangou, 2010). Adaptation refers to the process of bacteria 
acquiring short fragments of invading phage DNA and integrating them into their 
genomes (Brouns et al., 1993; Browne, Li, Chong, & Littman, 2005; Bult et al., 1996). 
Interference refers to the Cas complex binding CRISPR RNA (crRNA) from the CRISPR 
locus and cleaving foreign DNA which matches the previously integrated spacers which 
threaten to integrate into the host’s DNA (Agari et al., 2010). 
Engineering the Cas9 System 
Cas9 is composed of six domains, REC I, REC II, Bridge Helix, PAM Interacting, 
HNH and RuvC. REC I binds guide RNA; the role of REC II is not yet well understood; 
the Bridge Helix domain is crucial for initiating cleavage activity upon binding of target 
DNA; the PAM Interacting domain confers PAM specificity for discriminating between 
self and nonself sequences, and is responsible for initiating binding to target DNA; and 
HNH and RuvC are nuclease domains that cut single-stranded DNA  (Anders, 
Niewoehner, Duerst, & Jinek, 2014; Jinek et al., 2014; Nishimasu et al., 2014). The 
sgRNA is composed of two parts; tracrRNA which binds Cas9, paired to the crRNA, 
which base pairs with the target DNA, forming a heteroduplex(Cong et al., 2013; Jiang & 
Doudna, 2017). These two RNAs are oftentimes delivered as a single-guide RNA 
(sgRNA), where after complexing with Cas9, lead it to cut DNA at endogenous genomic 
loci adjacent to the PAM, as shown in human, mouse, and other mammalian species, 
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including the golden Syrian hamster as demonstrated by our laboratory (Cong et al., 
2013a; Fan et al., 2014).  
A critical step in genome editing is designing an efficient guide RNA to target the 
genomic site of interest while accounting for possible off-targets. Guide RNA scoring 
software is available for SpCas9, and some Cas9 variants, through many online tools 
which use metrics from large-scale, empirical data to optimize sgRNA design, to enable 
precise and efficient genome engineering (Doench et al., 2016). Recently, new rules for 
guide RNAs were discovered, where TT- and GCC-motifs located in the 4 PAM-
proximal bases of the targeting sequence block CRISR/Cas9-mediated gene editing 
(Graf, Li, Chu, & Rajewsky, 2019). Additional factors such as decreased chromatin 
accessibility, secondary structure formation, or potential off-target DNA sites may also 
affect the choice and efficiency of sgRNA design (Cong et al., 2013a).  
 
 
 
Figure 11. Indels from CRISPR/Cas9 Double Strand Breaks. Insertions or deletions 
(indels) detected via sequencing, in EMX1 locus of human 293FT cells edited by human 
codon-optimized SpCas9 plasmid (Cong et al., 2013). The red dashes represent deletions, 
and red letter is an insertion. Note the PAM sequence overlined in red, Cas9 cleavage site 
indicated by the purple arrow, and the protospacer in blue. 
 
 
 
The PAM is crucial for Cas9 binding genomic DNA, a sequence specific to the 
species of Cas9, but in most commonly used, SpCas9’s PAM is composed of three 
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nucleotides in the order NGG after the 3’ end of the protospacer sequence which occurs 
every 16bp on average within the human genome (Figure 11) (Cong et al., 2013; Hu et 
al., 2018). The frequency of the PAMs within a gene of interest is vital to the success of 
homology directed repair (HDR)-mediated gene editing, which require precise 
positioning and short cut-to-mutation distances (~10-20bp away), respectively, for 
efficient editing (Paquet et al., 2016). Due to the infrequency, or to overcome a great 
distance of NGG PAMs from genetic locus to be edited,  Cass proteins from more than 
20 bacterial species, requiring PAMs such as NGRRT, NGRRN, NNNNGATT, 
NNNNRYAC, NNAGAAW, or NAAAAC have mediated gene editing in a variety of 
cell types, while thousands more Cas proteins remain to be discovered (Amrani et al., 
2018; Kim et al., 2017; Kleinstiver et al., 2015; Koonin & Makarova, 2013). These 
orthologues’’ sequences are limited in their similarity, except for conserved HNH and 
RuvC nuclease domains, and vary highly in length (~900-1600 amino acid residues) 
(Jiang & Doudna, 2017). SpCas9 is the most commonly used Cas9 version with a length 
of 1,369 amino acids, which limit its application for therapeutics, where shorter 
orthologues such as Staphylococcus aureus Cas9 (SaCas9) which is 1kb shorter than 
Cas9 or Cas-X which was isolated from a non-pathogenic bacterium with the intent of 
reducing the human pre-existing adaptive immune response. These Cas traits are 
desirable therapeutic applications such as packaging into viral vectors like AAV (~4.7kb 
DNA storage) and preventing an immune response in those receiving treatment 
(Charlesworth et al., 2019; Kleinstiver et al., 2015; Liu et al., 2019; Wang et al., 2016).  
Although many new Cas9 variants are discovered frequently, none are more 
efficient than SpCas9 in editing mammalian cells with a PAM less restrictive than NGG 
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(Hu et al., 2018). Engineered variants of SpCas9 such as Sniper-Cas9, xCas9-3.7, Sp-
Cas9-NG and others have been developed by directed evolution, resulting in higher 
specificity to reduce off-targets, and/or greater PAM recognition flexibility, for 
increasing the number of genomic sites where genome editing may occur (Hu et al., 
2018; Lee et al., 2018; Mazhar, Hill, & McAuliffe, 2018).  
Another RNA-guided DNA-cutting nuclease known as Cas12a (Cpf-1) has been 
recently adapted for genome editing, which processes its own guide RNA and recognizes 
TTTV PAMs, generating staggered or “sticky” ends after DNA cleavage, 18-23nt distal 
to the target site (Yamano et al., 2016; Zetsche et al., 2015). Recently, Gao’s group 
(2017) has engineered Cas12a variants through structure-guided mutagenesis, which 
increased its targeting range three-fold, to one cleavage site per ~11bp in human coding 
sequences. These Cpf-1 TYCV and TATV PAM-recognizing variants show enhanced 
performance in human cells and high DNA-targeting specificity, qualities which are 
invaluable for editing NGG PAM-scarce loci (Gao et al., 2017). 
CRISPR/Cas9 DNA Breaks – DNA Repair  
One study in humans reported that DNA damage occurs naturally at an estimated 
20,000-100,000 times a day, with DSBs being the most deleterious (Khanna et al., 2001). 
Originally observed by gamma irradiation, DSB repair was theorized to use broken ends 
with homologs and later proven to use sister chromatin as templates for repair (Orr-
Weaver, Szostak, & Rothstein, 1981; Resnick, 1976). If not repaired, DSBs can induce 
apoptosis, loss of heterozygosity through copying sequences from sister chromatids, cell 
senescence, or cancer (Burma, Chen, & Chen, 2006).  
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The non-homologous end joining (NHEJ) pathway directs the religation of 
segregated DNA, while not requiring a homologous template. Due to the presence of 
repeats or microhomology, miscellaneous nucleotides at the DSB site are deleted to allow 
for rejoining of the strands (Figure 12) (Jasin & Rothstein, 2013; Weterings & Chen, 
2008). The steps of NHEJ include (I) DNA end recognition, (II) DNA end bridging, (III) 
DNA end processing, and (IV) ligation of broken ends, which result in insertion or 
deletion of DNA bases at the DSB site, making NHEJ pathway a generally unfavorable 
pathway for genome editing (Davis & Chen, 2013). 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Double Strand Break Repair Pathways. (Jasin & Rothstein, 2013). 
 
The Homology Directed Repair (HDR) pathway uses an undamaged DNA strand 
as a template for repairing the damaged strand, such as a sister chromatid or 
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synthetically-produced DNA (J. P. Zhang et al., 2017). The first step of HDR is 5’ to 3’ 
end resection, which leaves a 3’ ended single-stranded DNA (ssDNA) region 
(Kakarougkas & Jeggo, 2014). Replication protein A (RPA) quickly binds ssDNA tails to 
prevent secondary structure formation, followed by RAD51 tail binding, which displaces 
RPA, and promotes invasion onto the undamaged template and strand displacement, 
forming a D-loop structure which provides a 3’ end for DNA synthesis or gap filling by 
polymerase, resulting in a heteroduplex molecule called a double Holliday Junction (dHJ) 
(Figure 13) (Jasin & Rothstein, 2013; Kakarougkas & Jeggo, 2014). Many HDR avenues 
may follow, but to avoid cross-over events, endonucleases induce symmetrical incisions 
across the junctions, resulting in nicked duplex products (Shah Punatar, Martin, Wyatt, 
Chan, & West, 2017). The newly synthesized DNA strand disassociates from the D loop, 
dissolved by branch migration and topoisomerase activity of the BLM 
(Sgs1)/TOP3α/RMI1 complex, and anneals to the other DNA end, followed by end-
ligation which finishes the DNA repair event (Jasin & Rothstein, 2013).  
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Figure 13. Homology Directed Repair after Double-strand Break Formation. (Shah 
Punatar et al., 2017).  
 
The HDR pathway may be used to insert exogenous DNA sequences into the 
genome, enabling generation of site-specific knock-ins (Gutschner, Haemmerle, 
Genovese, Draetta, & Chin, 2016). HDR-mediated knock-in efficiencies may reach 10% 
in mammalian cells when used in conjunction with donor molecules which are necessary 
for providing a template for the cell’s repair machinery to read and insert altered gene 
sequences (Jasin & Rothstein, 2013). These homology donors may range from short 
single-strand oligodeoxynucleotides (ssODNs) with 50-100bp homology arms, to larger 
external linear sequences with circular or linearized donor template with 1kb or longer 
flanking arms to achieve knock-in of larger reporter genes, which has been achieved in 
many cell types, including human cells via CRISPR/Cas9-induced HDR (Chen et al., 
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2011; Radecke, Radecke, Cathomen, & Schwarz, 2010). According to findings from 
three groups, led by Wang (2016), Richardson (2016), and Prykhozhij (2018), ssODN 
optimization involves several factors including length, sense, symmetry, PAM mutations 
and chemical modifications. These groups found that an optimal ssODN design included 
a length of 120nt., antisense orientation, asymmetric alignment to the DSB (77bp 
upstream homology and 43bp downstream), a 1nt. PAM mutation and phosphorothioate 
modifications to prevent endonuclease cleavage, increasing HDR 3 to 10-fold in Zebra 
fish gene editing experiments. 
 
Figure 14. Estimated CRISPR/Cas9 Editing Frequencies. As Cas9 cuts further away 
from the mutation of interest, the lower the probability of isolating biallelically edited 
zygotic clones. Heterozygous (blue) frequency climaxes at 10-15 bp away. Frequency of 
homozygous wild type (green) increases with distance as frequency of homozygous 
edited (red) decreases (Paquet et al., 2016). 
 
In many instances, HDR is desired for knocking in a genetic sequence but it’s 
difficult to achieve due to lower efficiency when compared to NHEJ. In the case of 
single-nucleotide changes, HDR efficiencies depend largely on the distance-to-cut 
mutation, preferably <15bp (Figure 14) (Paquet et al., 2016). Other ways to increase 
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HDR events in cells include small molecule inhibitors of NHEJ, which are shown to 
increase point mutation generation by up to 4-fold in some cell lines (Riesenberg & 
Maricic, 2018). Alternatively, HDR booster chemicals SCR7, L755507, and Resveratrol 
increased HDR by nearly 2-3 fold, and in some cases as high as 50%  in screened 
colonies (Li et al., 2017). Additionally, Integrated DNA Technologies (IDT) has 
developed a proprietary Alt-R HDR chemical enhancer (Schubert, Thommandru, and 
Wang, 2018). Although HDR enhancers and NHEJ inhibitors have increased HDR in 
many cases, these chemicals do not have universal effects on all cell types and targeted 
genes and may not increase efficiency or may alter cell growth (Riesenberg & Maricic, 
2018). 
Adenine Base Editors 
Gaudelli (2017) from David Liu’s group at MIT developed an Adenine Base 
Editor which converts A∙T to G∙C pairs in genomic DNA without DSBs. Her 7th 
generation Adenine Base Editor (ABE7.10) contains a Cas9 nickase fused to Escherichia 
coli TadA, a tRNA adenosine deaminase, which was adapted through extensive directed 
evolution and protein engineering to act on DNA instead of its usual RNA substrate. She 
reported that ABE7.10 requires an NGG PAM and a 20nt guide RNA to target genomic 
loci to convert A to G within a base editing window which spans 5 nucleotides in 
protospacer positions 13-17 from the PAM and is sometimes referred to as window 
positions 4-8 on the PAM-containing strand (Figure 15A). She also described the 
mechanism for base conversion where Cas9n binds and nicks genomic DNA, and TadA 
hydrolytically deaminates adenosines to inosine within the editing window. In order to 
complete the base conversion, Gaudelli reported that during subsequent DNA repair or 
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replication, inosine is permanently replaced by guanosine and the complimentary 
thymine base is changed to cytosine, and virtually no indels are generated (typically 
≤0.1%). 
If no NGG PAMs are available to adjust the target adenine within the editing 
window, ABE 7.10 cannot be used to correct the mutation. To increase PAM flexibility, 
Hu (2018) from David Liu’s group engineered the SpCas9 so that it recognizes NG, 
GAA, and GAT PAMs, and fused it to TadA, resulting in xCas9(3.7)ABE7.10. He notes 
in the study that editing efficiencies with these candidate PAMs vary by selection and 
additionally by guide sequence design. 
Additionally, to improve the already reliable ABE7.10, it was optimized by 
modification of nuclear localization signals and codon usage, and ancestral reconstruction 
of the deaminase component to increase plasmid expression Koblan (2018) from David 
Liu’s group. The resulting ABEmax editor corrects mutations ~5 to 7-fold more 
efficiency than ABE7.10 and generates indels rarely (≤1.6%) although elevated from the 
virtually undetectable indel levels of ABE7.10 (Koblan et al., 2018). 
 
Figure 15. Adenine Base Editor 7.10 Editing Window (A) Adenine DNA Base Editor 
and (B) Adenine RNA Base Editor (REPAIR). DNA ABEs contain one WT TadA 
deaminase and one evolved TadA deaminase to act on DNA. Base editing window is 
shown for ABE 7.10 (Molla & Yang, 2019). 
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It was also discovered that the editing window may be widened to accommodate 
mutations which fall outside the editing window by Ryu’s group (2018). By adjusting the 
guide length 1-2nt for a desired position (Figure 16), ABE editing windows are 
broadened to protospacer positions 12-20. He showed that adenine base editing at the 
distant 18 and 19 protospacer positions reached 20% in HEK293T cells, demonstrating 
that the editing window may be adjusted to accommodate adenine base conversion at 
distant positions which are unattainable with a 20nt. guide RNA. 
Figure 16. Base Editing with Broadened Protospacers. AG editing in HEK293T 
cells outside of conventional protospacer positions 12-17 by delivering lengthened 
sgRNAs. About 10-12% normal efficiency at protospacer position 19 (blue arrow), 
compared to that of the ideal target position 16. Since the HERDA mutation lies at 
position 19, delivery of 22nt. sgRNA could allow for base editing as high as 10% (Ryu et 
al., 2018). 
Cas13 mRNA Editor (REPAIR) 
In 2017, Gootenberg, Abudayyah, and Cox (2017) from Feng Zhang’s lab at MIT, 
developed an RNA base editing system composed of type VI CRISPR-Cas which 
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contains the programmable single-effector RNA-guided RNase, Cas13 which is capable 
of robust knockdown and RNA editing by dCas13 to direct A to I conversion by 
Adenosine Deaminase that acts on RNA (ADAR) in mammalian cells, referred to as 
RNA Editing for Programmable A to I Replacement (REPAIR). They reported that 
Cas13 does not require a PAM to target RNA, but is differentially regulated by accessory 
proteins Csx27 and Csx28. They designed 51 nucleotide sgRNA to target mRNA 
transcripts with REPAIR, containing a C mismatch at the target A in the guide. This 
“base flip” directs the ADAR2 enzyme to deaminating the target A, exposed in a bulge or 
loop (Matthews et al., 2016). They reported that efficiency of REPAIR is dependent on 
the position of the target A in the guide sequence (as designated by the C base flip), 
where the 34th position from the direct repeat provides the best editing, and a 5' G may 
be appended to cap the guide which increases efficiency. 
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CHAPTER III 
MATERIALS AND METHODS 
Cell Culture 
Equine skin sample collections for genetic analysis and genome editing were 
taken from a privately owned HERDA-affected horse named Max, and a Utah State 
University owned horse named Badger (IACUC-2771). The biopsies were sanitized with 
ethanol, washed in PBS, submerged in DMEM while resectioned into tiny pieces, and 
placed in at 100mm cell culture dishes with 10% or 20% FBS DMEM for several days at 
37o C, 5% CO2 to allow for outgrowth of fibroblasts from the tissue fragments (Table 1). 
The cells were then trypsinized, expanded in T-75 flasks, and cryopreserved.  
Gene Targeting in HERDA Equine Fibroblasts 
To target the PPIB genomic loci in HERDA equine fibroblasts, RNA guides were 
designed with Benchling life science data management/collaboration platform tool 
(https://www.benchling.com). Primers for sgRNA synthesis and oligonucleotide repair 
templates for the targeting sites were synthesized by Integrated DNA Technologies (IDT, 
Iowa, USA). sgRNAs were synthesized “in house” via GeneArt™ Precision gRNA 
Synthesis Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. 2 μg 
sgRNAs were complexed with 2 μg Cas9 protein (Trucut©, Thermo Fisher Scientific) at 
room temperature for 15-30 minutes, forming the ribonucleoprotein (RNP) (Table 1). 
5x105 HERDA fibroblasts were transfected using AMAXA 4D nucleofection (Program 
EN-150) according to the manufacturer’s protocol with sgRNA3 RNP and ssODN RC7 
(PAGE purified single stranded DNA donor oligonucleotide (IDT) 100uM final 
concentration) (Table 3). The CRISPR/Cas9 RNPs and ssODN RC7 were transfected into 
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fibroblasts derived from a HERDA-affected horse named Max (Hrd/Hrd). Negative 
controls were derived from untransfected Max cells and positive controls from non-
affected and untransfected horse (WT/WT) fibroblasts. 
Cells were grown for 2 days, after which half of cells were harvested for 
genotyping. Genomic DNA was extracted with the DNeasy blood and Tissue Kit 
(Qiagen, Cat No./ID: 69506) according to the manufacturer’s protocol (Table 1).  
 The PPIB gene containing the HERDA mutation was amplified using PPIBex1F 
forward primer and PPIBex1R reverse primer (Table 2). Each 50 μl PCR reaction was 
assembled with 0.25 Ex Taq Polymerase (Clonetech) according to the manufacturer’s 
instructions using 1 μM forward and reverse Pub1 primers. PCR reactions were carried 
out under the following conditions: 98⁰C for 2 min, then 32 cycles of 98⁰C for 10 sec, 
60⁰C for 30 sec, 72 for 30sec, then final extension 72⁰C for 5 minutes. PCR products 
were verified by comparison to DNA standard (1-kb Plus DNA Ladder) and to WT or 
HERDA controls on a 2% agarose gel with SYBR Safe DNA stain (Life Technologies) 
(Table 1). 2-3 μl of PCR product were digested with Stu1 (Eco 1417) (Thermo Fisher 
Scientific) at 37⁰C for 15 minutes to check for editing, or the with Taa1 (Thermo Fisher 
Scientific) with the same parameters to check for indels. PCR fragments were loaded 
onto a 2% agarose gel and compared to WT and HERDA control digests along with 1-kb 
Plus DNA ladder (Table 1). Since Stu1 cuts PCR product containing HERDA, bands at 
250bp were classified as WT, and those lower at 120bp were considered HERDA. Gel 
image analysis was performed using Image J software (1.47p, NIH) to quantify band 
relative intensity for knockout and editing efficiencies. SYNTHEGO ICE, a CRISPR 
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poly peaks parser analysis tool, was used to found in mixed PCR sequences for 
estimating INDEL species in single colonies or pooled PCR. 
HERDA Single-Colony Selection:  
One-third of transfected cells were detached 2 days after transfection and pipetted 
into 2mL fresh media for counting and establishing single-cell derived colonies by 
limiting dilution, and the other two-thirds were cryopreserved. The average cell count 
was performed with a hemocytometer, where the appropriate volume was pipetted into 
50mL fresh 20% FBS DMEM (Thermo Fisher Scientific) and distributed to 5 96-well 
plates (Thermo Fisher Scientific) (Table 1). Cells were incubated for 10-15 days and 
screened for single-cell colonies within cell-positive wells. Upon reaching at least 80% 
confluency, cells were transferred to 24-well plates, and then to 6-well plates where one-
half of the cells were harvested for genotyping. If cells had monoallelic or biallelic 
editing, 5x105 cells were cryopreserved per cyrovial by addition of 10% DMSO to 90% 
DMEM (20%FBS), and placed in a -80oC freezer, then transferred to liquid nitrogen the 
next day. 
Gene Targeting with Base Editors xABE and ABEmax 
xCas9(3.7)-ABE(7.10) plasmid (Addgene #108382), pCMV ABEmax plasmid 
(Addgene #112095), guide vector PFYF 1320 EGFP Site#1 (Addgene plasmid #47511), 
and pX330-SpCas9-NG (Addgene plasmid #117919) were purchased from Addgene 
(https://www.addgene.org) (Table 1). These plasmids were received as bacterial stabs. To 
amplify these plasmids, bacterial stabs were spread on agarose dishes (+amp) and 
incubated at 37⁰ C for 12 hours. Colonies were selected and inoculated in 2ml amp+ LB 
broth and cultured at 37⁰ C with shaking at 225rpm for 12 hours. xABE and pFYF1320 
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plasmid-carrying colonies were isolated by Gene JET Plasmid Miniprep kit (Thermo 
Scientific) according to manufacturer’s instructions, verified by enzyme digest and gel 
electrophoresis (Table 1). Plasmids for sgRNA expression were constructed using one-
piece blunt-end ligation of a PCR product with the KLD kit (New England Biolabs) 
according to the manufacture’s protocol (Table 1). PCR was performed using Ex Taq 
Polymerase (Clonetech) with guide sequence-containing primers and the guide 
expression plasmid pFYF1320 as a template according to the manufacturer’s instructions. 
DNA vector amplification was carried out using single-use JM109 competent cells 
(Promega). Bacteria were transformed, cultured, and verified according to the 
manufacturer’s instructions and as stated above.  
 Plasmid Transfection:  2 μg plasmid (xABE, ABEmax, or pX330-SpCas9-NG, 
and 2.5 μg of sgRNA expression plasmid were mixed with 100 μl P3 solution (LONZA) 
and transfected into 5x105 HERDA cells according to LONZA protocol; cells were 
cultured and genotyped as stated according to methods stated above. The same procedure 
was carried out with 2 μl GFP plasmid (LONZA) as a positive control, where although 
not quantified, nearly every fibroblast was fluorescent under blue/UV light. 
REPAIR Plasmid Preparations: pC0054-CMV-dPspCas13b-longlinker-
ADAR2DD(E488Q/T375G) (Addgene plasmid # 103870), pC0043-PspCas13b crRNA 
backbone (Addgene plasmid # 103854), and pC0039-CMV-dPspCas13b-GS-
ADAR2DD(E488Q) (Addgene plasmid # 103849) were purchased from Addgene 
(https://www.addgene.org) (Table 1). pC0043 guide expression vector was linearized in 
the following 100 μl reaction: 1500 ng BbsI-linearized vector DNA (pc0043), 10 μl 
cutsmart buffer, 2 μl BbsI-HF, 85 μl H2O. The reaction was incubated at 37⁰C for 1 hour 
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and inactivated at 65⁰C for 20 minutes. Digest with BbsI was purified using QIAquick® 
PCR purification kit (Ref# 28106). For ligation, primers were ordered from IDT, melted 
at 95⁰C for 2 minutes, then annealed by cooling to 25⁰C on bench top. Ligation reaction 
included 2 μl T4 DNA ligase buffer, 50 ng vector DNA (pc0043 crRNA backbone), 2.5 
ng annealed primers, 1 μl T4 DNA ligase (M0202), and 14 μl water (New England 
Biolabs). Concentration of insert oligos was calculated using the NEB calculator. 
Ligation proceeded for 10minutes on benchtop at room temperature and was inactivated 
by incubation for 10 minutes at 65⁰C. 5 μl ligation product was transformed into JM109 
competent cells (Promega) according to manufacturer’s instructions and incubated 
overnight at 37⁰C with shaking (225rpm) on amp+ agarose. Colonies were selected and 
inoculated in 2ml LB broth and cultured at 37⁰ with shaking at 225rpm for 12 hours. 
Plasmids were isolated with the Gene JET Plasmid Miniprep kit (Thermo Scientific) 
according to manufacturer’s instructions and verified by enzyme digest, gel 
electrophoresis, and sequencing (ACGT Inc.; m13R primer 5′-
GGAAACAGCTATGACCATG- 3′). Colony 3.3 (positive for insert into pc0043) was 
added to 50ml LB broth and incubated overnight at 37⁰C with shaking (225rpm). The 
plasmid was purified from the bacteria using Plasmid Plus Midi kit (Qiagen, Ref# 
12943).  
REPAIR Transfection: 1.5 μg pC0054 or pC039 and 4 μg of sgRNA expression 
plasmid (pC0043+insert) were mixed with 100 μl P3 solution (LONZA) and 5x105 
HERDA equine cells and transfected according to LONZA protocol and repeated with 
half the amount of plasmid. Cells were harvested after 48 hours in order to harvest 
optimal amounts expected edited RNA transcripts. Medium was removed and cells were 
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lysed by addition of 300 μl lysis buffer with 2-mercaptoethanol. Lysate was homogenized 
by passing through an 18-gauge syringe needle. RNA was purified from lysate using the 
PureLink® RNA Mini Kit (Life technologies, Cat# 12183018A) according to 
manufacturer’s instructions. RNA was treated with DNase I after purification to assure 
highly pure RNA without genomic DNA contamination (5 μl RNA, 2 μl DNaseI+buffer,3 
μl water, room temperature incubation for 15min, 65⁰C for 10 min).  cDNA was 
synthesized using the SuperScriptTM III First-Strand Synthesis Super Mix according to 
the manufacturer’s instructions (Invitrogen, Thermo Fisher Scientific). Each 20 μl PCR 
reaction was assembled with 0.2 μl Ex Taq Polymerase (Clonetech) according to the 
manufacturer’s instructions (2 μl buffer, 1.6 μl dNTP) using primers PPIBF2-RT, 
PPIBR5-RT (Table 2) and 2 μl cDNA from previous reaction (unquantified). PCR 
reactions were carried out under the same conditions as described above and genotyped 
in the same manner.  
 
Reagent Company Catalogue # 
Cas9 protein (Truecut©) Thermo Fisher Scientific A36498 
GeneArt™ Precision gRNA 
Synthesis Kit  Thermo Fisher Scientific A29377 
KLD kit (two tubes: enzyme and 
buffer) New England Biolabs M0554S 
SuperScriptTM III First-Strand 
Synthesis Super Mix  
Invitrogen, Thermo 
Fisher Scientific  
18080400 
pFYF1320 EGFP Site#1 Addgene 47511 
 pAsCpf1(TYCV)(BB) (pY211)  Addgene 89352 
pC0043-PspCas13b crRNA 
backbone Addgene 103854 
pC0039-CMV-dPspCas13b-GS-
ADAR2DD(E488Q) Addgene 103849 
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pC0054-CMV-dPspCas13b-
longlinker-
ADAR2DD(E488Q/T375G) Addgene 103870 
xCas9(3.7)-ABE(7.10) Addgene 108382 
pCMV_ABEmax Addgene 112095 
pX330-SpCas9-NG Addgene 117919 
Stu1 (Eco 1471)  Thermo Fisher Scientific FD0424 
Taa1  Thermo Fisher Scientific FD1364 
BbsI New England Biolabs R3539 
PureLink™ RNA Mini Kit Thermo Fisher Scientific 12183018A 
Agarose A Bio Basic AB0013 
DNA ladder Clonetech 3412B 
Nunc™ Biobanking and Cell 
Culture Cryogenic Tubes Thermo Fisher Scientific 347783 
Trypsin-EDTA (0.05%), phenol red Thermo Fisher Scientific 25300054 
DMEM Thermo Fisher Scientific 11995115 
DPBS Thermo Fisher Scientific 14190250 
100mm Cell culture dish Falcon,  Life Sciences  
FBS Thermo Fisher Scientific 16000044 
DMSO Sigma-Aldrich M81802 
Gene JET Plasmid Miniprep kit  Thermo Fisher Scientific K0502 
JM109 competent cells  Promega 200235 
T4 DNA ligase  New England Biolabs M0202 
96-well Clear Flat Bottom TC-
treated Culture Microplate Falcon,  Life Sciences 353072 
LB Agar, Miller (Powder) Fisher Scientific BP1425500 
Amplicillin Sigma-Aldrich A5354  
Table 1. List of Reagents. Reagents used in experiments with respective companies and 
catalogue numbers. 
 
Name Sequence 
PPIBex1F (Pub1F) 5’-CGGTGGATGCTGCGTTTCT-3’ 
PPIBex1R (Pub1R) 5’-TCCTAGGCTGGCTTGGGC-3’ 
PPIBF2-RT 5’-CTGTCTTCTTCCTGCTGTTGCC-3’ 
PPIBR5-RT 5’-TCTCCTTCAGACTACGGGGT-3’ 
Table 2. PCR primers 
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ssODN 
Name 
Sequence 
length 
(nt.) 
symmetry sense 
RC7 
5’−CAGGCAGGTCTGGAGAGGGGAGGCC
AGATCTTGACAGTGACTTTAGGCCCCTT
CTTCTTCTCATCGGCCGTGGAGGGTCCTG
GCAACAGCAGGAAGAAGA−3’ 
100 asymmetric 
Anti-
sense 
*120nt 
5’−AGGACCCTCCACGGCCGATGAGAAG
AAGAAGGGGCCTAAAGTCACTGTCAAA
GTCTGGCCTCCCCTCTCCAGACCTGCCTG
GCGAGGCCCGCCCTGGGGTCCGGCCTCG
GTGCCGCTGGT−3’ 
120 asymmetric sense 
Table 3. ssODN Designs. Sequences of ssODNs used in fibroblast transfections for 
editing the HERDA-causing mutation in fibroblasts. *this ssODN was not shown to mediate 
editing in pooled RFLP analysis, but may yet be useful for increasing HDR efficiency since it was a 
late-stage ssODN design (Wang et al., 2016) for sgRNA3 that never had single-cell colonies 
derived from a transfection. 
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RESULTS 
 CRISPR/Cas9-medaited Gene Editing in Fibroblasts 
sgRNA Designs, PCR-RFLP, Donor Oligonucleotides 
The first approach used to edit the HERDA (c.115G>A) mutation in fibroblasts 
was with CRISPR/Cas9 and ssODN templates. Since HDR efficiency in gene editing 
decreases dramatically when DSBs are generated >15bp from the mutation, we designed 
sgRNA1 (Table 4), which recognizes an AGG PAM resultant from the HERDA-causing 
mutation, to generate indels 3bp upstream from the mutation. Reported as a unit less 
on/off target score where values closer to 100/100 represent the best guide, sgRNA 3 had 
the best predicted on/off target score, designed to generate indels 15bp downstream of the 
HERDA mutation (Benchling guide scorer) (Table 4, Figure 17).  
 
 
 
  
 
  
 
Figure 17. Targeting the HERDA-causing Mutation with CRISPR/Cas9. A segment 
of genomic DNA from the horse PPIB gene that contains the HERDA-causing mutation 
(red). Annotations include sgRNA sequences (highlighted in corresponding colors), their 
corresponding PAM locations (underlined in brown).  
Equine PPIB Gene 
~6kb
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Guide name Sequence (5’ to 3’) Mutation-
to-cut 
distance 
(bp) 
Predicted 
on/off 
target 
scores 
Observed 
indel 
efficiency  
sgRNA1 CGGCCGATGAGAAGAAGAAG 3 59/26 none 
sgRNA3 GAGGCCTAAAGTCACTGTCA 15 69/51 90% 
sgRNA4  AGGCCTCTTCTTCTTCTCAT 11 53/34 none 
sgRNA7 GCTGTTGCCAGGACCCTCCA 23 62/32 15% 
PX330-NG-4 GAGAAGAAGAAGAGGCCTAA 4 n/a 55% 
sgRNA3x22 AAGAGGCCTAAAGTCACTGTCA 15 n/a n/a 
Table 4. Guide RNA Designs. Details of sgRNAs tested in equine fibroblasts with the 
HERDA-causing mutation. 
 
Testing sgRNA Efficiency 
A major challenge to designing sgRNAs for editing the HERDA-causing mutation 
was that three GAA repeats are found upstream of the mutation, resembling a figurative 
NGG PAM “desert”. We also suppose that these GAA repeats formed secondary 
structures when incorporated into sgRNAs, preventing sgRNA1 and sgRNA4, which 
spanned these GAA repeats, from generating indels (analyzed via RFLP). SgRNA 3 was 
selected for gene editing because it generated indels 15bp downstream of the mutation, 
with high efficiency (Figure 18C), while sgRNA 7 was the only other guide to generate 
indels but at much further distance of 23 nucleotides from the HERDA-causing mutation.  
Donor Oligo Design 
Several oligonucleotides were designed for editing the HERDA-causing mutation 
according to the findings of the Richardson (2016), Kankan (2016), and Paquet (2016) 
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groups, for gene editing (Table 3). These oligonucleotides differed by length, symmetry 
around the DSB, and sense with respect to the PAM-containing strand. An antisense 
asymmetric ssODN donor template with 69 and 31 nucleotide homology arms was 
designed, named RC7 (Reverse compliment 7). This ssODN carried two mutations: 
R39G to edit HERDA and the sgRNA3 PAM-blocking mutation (AGGAGA) (Figure 
18A). 
Gene Editing Efficiency 
CRISPR/Cas9 and ssODN (sgRNA3 and RC7) were transfected in fibroblasts 
established from a HERDA-affected horse, named Max, which is homozygous for the 
HERDA-causing mutation. RFLP analysis revealed that sgRNA 3 indel formation was 
90% efficient (Figure 18C) while fragments resistant to Stu1 reached 20% (Figure 18D), 
indicating that editing occurred. 
 
 
 
 
 
 
 
INDEL positive 
 
 
 
L       WT       Max 
sgRNA 3   
& ssODN L          WT          Max 
sgRNA 3   
& ssODN L          WT          Max 
sgRNA 3   
& ssODN 
B C D 
                5’- CTCATCGTGGGCTCTGTCTTCTTCCTGCTGTTGCCAGGACCCTCCACGGCCGATGAGAAGAAGAAGAGGCCTAAAGTCACTGTCAAGGTCTGGCCTCCCCTCTCCAGACCTGCCTGGCGAGGCCCGCC -3’  
             A     3’- AGAAGAAGGACGACAACGGTCCTGGGAGGTGCCGGCTACTCTTCTTCTTCCCCGGATTTCAGTGACAGTTCTAGACCGGAGGGGAGAGGTCTGGACGGAC -5’ 
  
RC7 Antisense 
asymmetric 
oligonucleotide 
PAM sgRNA 3 site 
PAM mutation R39G 
A 
HERDA 
mutation 
(c.115 G>A) 
gDNA 
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Figure 18. CRISPR/Cas9 pooled DNA RFLP Analysis for Indels and Editing. A) 
Genomic sequence and donor oligonucleotide RC7 (antisense, asymmetric) shown for 
site PPIB G39R editing. B) sgRNA3 and ssODN RC7-transfected HERDA pooled PCR 
product with WT and HERDA (Max) controls C) Taa1 enzyme digest which is 
unaffected by HERDA point mutation editing or the PAM-blocking mutation, revealing 
indels only, as uncut upper band and D) modified (diluted to 30 μl) Stu1 digest, revealing 
editing and large indels as uncut upper band (blue arrow). 
 
Screening Single-cell Derived Colonies 
 In order to determine point mutation editing efficiency in fibroblasts, 41 single-
cell colonies were isolated and analyzed with RFLP and confirmed by sequencing. 
Colonies 3D6, 1B6, and 3D5 had monoallelic editing and one colony, 3B2, had biallelic 
editing. These colonies were cryopreserved for future experiments (Table 5). Overall 
editing efficiency observed in single colony selection was 9.8% (4/41), while monoallelic 
and biallelic frequencies were 7.3% and 2.4% respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
3
B
1 
1B6 L WT Max 
C 
3D5 L WT Max D 
3B2 3D6 L L WT Max 
A B 
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Figure 19. CRISPR/Cas9 Single-Cell Colony RFLP Analysis and Sequencing. A) 
colony 3D6 is monoallelically edited, B) 3B2 is biallelically edited, C) 1B6 is 
monoallelically edited, and D) 3D5 (although small peaks) likely monoallelically edited. 
RFLP fibroblast Controls: WT = WT/WT alleles, Hondo = WT/Hrd alleles, Max = 
Hrd/Hrd alleles. Unlabeled lanes indicate unedited or indel-containing colonies. Blue 
arrows and indicate point mutation editing (circled in red); green arrows indicate the 
PAM-blocking mutation editing (circled in purple).  
 
Colony 
Name 
Genotype Vials 
Cryopreserved 
Cells per 
cryovial 
Confluency at 
cryopreservation 
Notes 
3D6 WT/4-6bp 
Deletion 
5 5x105 90% Very fast growth and good 
morphology 
3B2 WT/WT 2 5x105 90% 
 
3D5 WT/HRD 2 5x105 90% 
 
1B6 WT/1bp 
Deletion 
1 5x105 60% 
 
Table 5. Gene Edited HERDA-equine Single-Cell Colonies. Colonies’ names and 
genotype derived from sgRNA 3 and RC7 ssODN transfection and single-colony 
selection. 
 
ABEmax 
 Since sgRNA3 was highly efficient (90%), it was also used to base edit the 
HERDA-causing mutation as the guide for ABEmax. sgRNA3 was lengthened by two 
nucleotides for broadening the editing window to positions 12-19. This guide RNA 
modification gave ABEmax access to the HERDA-causing mutation at position 19 
(Figure 20).   
 
 
 
 
 
Figure 20. ABEmax Editing Diagram. The equine PPIB genomic sequence to be edited 
with ABEmax contains the sgRNA3x22 sequence (annotated in green) and its 
 22a21 20 a19 a18 a17 a16 a15 a14 a13 a12 a11 10 9   8   7   6   5   4   3   2  1  
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corresponding PAM location (underlined in brown). The curly bracket indicates the 
expanded base editing window location (positions 12-19) with the lengthened 22 
nucleotide sgRNA. Complimentary strands are separated to demonstrate base editing 
window.  
 
After transfecting fibroblasts carrying homozygous HERDA mutation, gene 
editing was not detected in pooled cells with the PCR-RFLP assay (Figure 21A) but after 
deriving 20 single-cell colonies, monoallelic base editing was observed in three colonies 
and confirmed by Sanger sequencing (Figures 21C and D). Seven other colonies were 
also resistant to Stu1 digestion but unfortunately showed an unspecific PCR band just 
below 250bp also apparent after Stu1 digestion (Figures 20B and C). When sequenced, 
mixed peaks made the chromatogram difficult to interpret, indicating that the PCR 
products contain an unrelated sequence and are unspecific bands, which can be further 
investigated through TA cloning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
L        WT          Max       ABEmax         A 
L       1        2        3        4       5       6       7       8        9      10 L       11       12     13      14      15     16       17       18     19    20 
L     1       2       3      4      5      6       7       8       9    10     11     12    13    14    15     16    17    18     19    20 B 
C 
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Figure 21. ABEmax Single-cell Colony RFLP and Sequencing Analysis. A) Pooled 
RFLP for transfection with ABEmax and sgRNA3x22 showing no HERDA-edited cells. 
B) PCR product from single and mixed colonies isolated from a 96-well plate. C) Digest 
with Stu1 for editing detection. Colonies 1, 17, 19 show monoallelic editing. Colonies 3-
6, 12-14 show editing and another possible indels (extra band).D) Sequence results from 
single-cell colonies 1, 17, and 19 show double-peaks at the HERDA mutation, revealing 
monoallelic adenine base editing, without indels. HERDA is circled in red and the blue 
arrow indicates the double-peaks characteristic of heterozygotes. 
D 
Colony 1 
Colony 19 
Colony 17 
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DISCUSSION 
HERDA is an increasingly problematic genetic disease that remains difficult to 
resolve in elite Quarter Horses throughout the world. “Breeding out” the disease by 
carefully genotyping registered Quarter Horses for the HERDA-causing mutation may 
reduce the spread of the genetic disease, but given the HERDA-causing mutation 
frequency among elite American Quarter Horses, it is unlikely. Also, since there are no 
effective treatments for HERDA-affected horses, they are oftentimes euthanized. Gene-
editing technology provides an opportunity to correct the HERDA-causing mutation. 
In my thesis research, two gene editing strategies were successful in correcting 
the HERDA-causing mutation in horse fibroblasts cultured from a HERDA-affected 
horse. First, CRISPR/Cas9 nuclease with an ssODN template corrected either one or both 
alleles in ~10% of transfected cells. Sanger sequencing confirmed that three single-cell 
colonies derived from the transfection were edited monoallelically, and one biallelically. 
These four colonies were cryopreserved with the goal of cloning the first gene edited 
horses in this breeding line without HERDA. The second strategy used was adenine base 
editing where ABEmax monoallelically corrected HERDA in 3 single-cell colonies 
derived from a transfection. Seven other colonies showed likely editing, in which case 
total ABEmax editing efficiency would be 55%, but an unspecific PCR band prevented 
their genotyping by sequencing. Further investigation is needed to characterize the 
genetic alterations in these colonies. 
Transfection via nucleofection maximized the efficiency of the guide RNA used 
for CRISPR/Cas9, generating 90% indels. Detecting editing in pooled cells with the 
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PCR-RFLP assay was challenging, and determining editing efficiency from single-cell 
colonies proved more reliable, but also time and work intensive. It is possible that gene 
edited loci are selected against during PCR and/or digested in concentrated Fast Enzyme 
Digest reactions. When enzyme digests were diluted to 30ul reactions, digests from 
pooled DNA showed editing. Nevertheless, increased editing efficiency is paramount to 
correcting HERDA in affected equine.  
Novel CRISPR tools emerge at an accelerated rate, but their applicability to many 
species, including equine, is unknown. We employed emerging gene editing techniques 
to genetically edit equine fibroblasts homozygous for the HERDA-causing mutation and 
demonstrated that both CRISPR/Cas9 combined with an ssODN and ABEmax are 
efficient in editing the equine genome.  
Although development may be costly to develop for actual treatment, we foresee 
their use in gene editing fibroblasts established from champion Quarter Horses which 
carry the HERDA-causing mutation followed by cloning animals from using the 
mutation-corrected fibroblasts as nuclear donors. Cloning these performance horses could 
offer horse breeders more flexibility in selecting mating pairs as edited clones could 
propagate these elite genetic lines without instances of HERDA.  
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CONCLUSIONS 
 
The PPIB HERDA (c.115 G>A) mutation was efficiently targeted by 
CRISPR/Cas9, generating 90% indels with sgRNA3 with a 15bp mutation-to-cut 
distance. Cas9 nuclease-mediated editing reached 10% in HERDA-affected equine 
fibroblasts. ABEmax was also used to target the HERDA mutation with sgRNA3, 
lengthened 2nt. (sgRNA3x22). This allowed for using the highly efficient sgRNA3 with 
ABEmax to edit HERDA at protospacer position 19, observed at 15% editing in single-
cell colonies, but may be as high as 55% upon further analysis of unspecific PCR bands. 
 Other new technologies that emerged during this project were tested in HERDA-
affected equine fibroblasts, including other Adenine Base Editors—xABE and REPAIR, 
Nureki’s SpCas9-NG, and the Cpf-1 TYCV variant. Editing was not achieved with these 
tools, except SpCas9-NG, which generated 50% indels only 4bp from the HERDA-
causing mutation. Single-cell colonies from SpCas9-NG and ssODN transfections are 
needed to determine editing efficiency, which were not analyzed due to time constraints. 
 Out of the 41 single-cell colonies derived from the CRISPR/Cas9 ssODN 
transfection, four were edited—three monoallelically and one biallelically. These four 
colonies were cryopreserved for later use in somatic cell nuclear transfer. Editing the 
HERDA-causing mutation in horses may demonstrate whether the mutation is 
responsible for high performance or if other genetic components independent of the 
mutation contribute to their high performance. This precise gene editing could also 
provide an alternative to “breeding out” the HERDA-causing mutation by retaining elite 
performance horse genetics in edited clones, used for breeding.  
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Additionally, HERDA gene therapies based on CRISPR/Cas9 and Adenine Base 
Editor technology, which corrected the mutation in horse fibroblasts, could improve 
affected equine health and performance. Restoring normal collagen folding, even at low 
rates, could help affected horses perform in the American Quarter Horse industry, thus 
reducing animal suffering and investment loss by owners. 
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